NCT05955040

Brief Summary

This is a randomized controlled trial comparing the outcomes of treatment and non-treatment of elevated blood pressures in early pregnancy.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Jul 2023

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 1, 2023

Completed
1 month until next milestone

Study Start

First participant enrolled

July 11, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 20, 2023

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 6, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 6, 2024

Completed
Last Updated

November 21, 2024

Status Verified

November 1, 2024

Enrollment Period

10 months

First QC Date

June 1, 2023

Last Update Submit

November 19, 2024

Conditions

Outcome Measures

Primary Outcomes (16)

  • Treatment of elevated blood pressures

    Patient age

    through study completion, an average of 1 year

  • Treatment of elevated blood pressures

    BMI

    through study completion, an average of 1 year

  • Treatment of elevated blood pressures

    delivery weeks

    through study completion, an average of 1 year

  • Treatment of elevated blood pressures

    systemic vascular resistance

    through study completion, an average of 1 year

  • Treatment of elevated blood pressures

    heart rate

    through study completion, an average of 1 year

  • Treatment of elevated blood pressures

    blood pressure

    through study completion, an average of 1 year

  • Treatment of elevated blood pressures

    gravidity

    through study completion, an average of 1 year

  • Treatment of elevated blood pressures

    parity

    through study completion, an average of 1 year

  • Treatment of elevated blood pressures

    abortions

    through study completion, an average of 1 year

  • Treatment of elevated blood pressures

    gestational hypertension

    through study completion, an average of 1 year

  • Treatment of elevated blood pressures

    inhouse days

    through study completion, an average of 1 year

  • Treatment of elevated blood pressures

    preeclampsia

    through study completion, an average of 1 year

  • Treatment of elevated blood pressures

    birth weight percentile

    through study completion, an average of 1 year

  • Treatment of elevated blood pressures

    Apgar 1 min

    through study completion, an average of 1 year

  • Treatment of elevated blood pressures

    Apgar 5 min

    through study completion, an average of 1 year

  • Treatment of elevated blood pressures

    NICU days

    through study completion, an average of 1 year

Secondary Outcomes (3)

  • ICG directed treatment

    through study completion, an average of 1 year

  • ICG directed treatment

    through study completion, an average of 1 year

  • ICG directed treatment

    through study completion, an average of 1 year

Study Arms (2)

Treatment Group

ACTIVE COMPARATOR

Treatment of elevated blood pressures (120 or greater systolic OR 80 or greater diastolic)

Drug: NifedipineDrug: Labetalol

Non-treatment Group

NO INTERVENTION

Non-treatment of blood pressures between 120-139 systolic and 80-89 diastolic

Interventions

Standard of care for treatment of elevated blood pressure during pregnancy

Treatment Group

Standard of care for treatment of elevated blood pressure during pregnancy

Treatment Group

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsPregnant women
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Patients presenting for obstetric care at Marshall University (Huntington office and Teays Valley office) between 12 and 16 weeks gestation with a systolic blood pressure of 120 or greater OR a diastolic blood pressure of 80 or greater. Eligibility for this study will be have blood pressures between 120-139 systolic and 80-89 diastolic. Randomization to control, labetalol, or nifedipine will be performed after patient consent.

You may not qualify if:

  • Patients already be on medication for hypertension.
  • Patients with the diagnosis of chronic hypertension
  • Patients with a BP of 140 or greater systolic OR 90 or greater diastolic (this meets criteria for chronic hypertension in pregnancy).
  • Patients actively using any illicit substance or have history of substance use disorder.
  • Patients who are actively consuming alcohol during pregnancy.
  • Patients with Type I or Type II Diabetes Mellitus.
  • Patients with end stage renal disease.
  • Patients less then 12 weeks gestation or greater than 16 weeks

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Marshall Obstetrics and Gynecology

Huntington, West Virginia, 25701, United States

Location

MeSH Terms

Conditions

HypertensionHypertension, Pregnancy-Induced

Interventions

NifedipineLabetalol

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular DiseasesPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Intervention Hierarchy (Ancestors)

DihydropyridinesPyridinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsEthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsSalicylamidesAmidesAmines

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Maternal Fetal Medicine

Study Record Dates

First Submitted

June 1, 2023

First Posted

July 20, 2023

Study Start

July 11, 2023

Primary Completion

May 6, 2024

Study Completion

May 6, 2024

Last Updated

November 21, 2024

Record last verified: 2024-11

Locations